DigiBiomarkers Awarded Runner-up Prize at Indiana Life Sciences Summit
On October 9th the DigiBiomarkers team pitched to a panel of seven judges in the final round o...
On October 9th the DigiBiomarkers team pitched to a panel of seven judges in the final round of the BioCrossroads Indiana Inject Tech Challenge. The panel consisted of individuals with expertise in healthcare, biopharma, and venture capital.
Thirteen companies working in healthcare IT entered the competition in early September, with three groups being selected for the final pitch session. DigiBiomarkers was awarded the runner-up prize of $6,000, which was announced at the Indiana Life Sciences Summit in Indianapolis.
DigiBiomarkers Moves to Final Round of the Indiana Inject Tech Challenge
BioCrossroads announces DigiBiomarkers as a finalist in the inaugural Indiana Inject T...
BioCrossroads announces DigiBiomarkers as a finalist in the inaugural Indiana Inject Tech Challenge.
Bharath Bynagari and Cian O'Donnell will be representing DigiBiomarkers at the Indiana Life Sciences Summit as finalists in the inaugural Indiana Inject Tech Challenge.
Three teams have made it to the finals of this competition, where teams working in healthcare technology are rewarded for enabling better patient health outcomes.
The Inject Tech challenge is catalyzing the creation of new, disruptive solutions designed to improve patient outcomes. The winners will be announced on Oct. 9 at the Indiana Life Sciences Summit with first place receiving $10,000 in prize money.
Indiana CTSI First Announces Support of DigiBiomarkers in Research Uses
Are you a researcher looking to further streamline your study’s design and collect more ...
Are you a researcher looking to further streamline your study’s design and collect more objective and multi-dimensional data from study participants?
The Indiana Clinical and Translational Sciences Institute (CTSI) has opened a new RFA for funding to use a new research tool from the Indiana Biosciences Research Institute (IBRI) and MavenSphere Inc. called DigiBiomarkers.
DigiBiomarkers is a HIPAA-compliant, cloud-based mobile and web application platform for researchers that aims to collect real-time, continuous and objective digital data from study participants. The platform provides a user-friendly clinical study management tool kit that researchers can use to customize their studies. DigiBiomarkers also automates a traditionally time-consuming process—for both researchers and study participants—of pen-and-paper surveys and phone call reminders, in addition to enabling the capture of data about study participants’ activities and environment (if consented) from connected devices.
Cian O’Donnell, MS, a digital consultant at the IBRI, said DigiBiomarkers allows researchers to add more objectivity to subjective measures in their studies, especially where measurements may not be available.
O’Donnell said the digital biomarker information collected by the iOS app provides for a more “3D” view of research participants’ health from:
- Surveys: Collect common or novel survey data and participant-reported outcomes (e.g. pain, depression scale, quality of life)
- Activity Tasks: Select from a range of activity tasks to measure cognition, motor function, fitness and more using validated assessments on a study participant’s smartphone (e.g. Stroop test, timed walk and knee range of motion)
- Passive Data: Collect geo location, physical activity, temperature and weather data, plus data from all HealthKit-enabled devices with study participant’s consent
Duration of access to the DigiBiomarkers platform will be negotiable depending on the defined research projects and their goals.
DigiBiomarkers Technology Award
A new innovative application platform, DigiBiomarkers, has been develope...
A new innovative application platform, DigiBiomarkers, has been developed by Indiana Biosciences Research Institute (IBRI) in collaboration with MavenSphere, Inc., to facilitate the rapid deployment of tools based on Apple’s ResearchKit, HealthKit, and CareKit software frameworks to capture digital information from individuals or patients.
See Indiana CTSI news release: http://www.indianactsi.org/news_/new-mobile-research-tool-rfa/
DigiBiomarkers (www.digibiomarkers) enables a wealth of data to be captured from patients which has not been available up to this point in time, and brings more objectivity and efficiency to clinical trials, thus accelerating the pace of quality research. The opportunity to remotely and continuously monitor patients provides a more contextually valid picture of patient health, while increasing the number of data points researchers have from which to draw conclusions.
The Indiana CTSI is now offering access to this platform. Applications to this program are limited to a total of $10,000 for customization of the software.Duration of the project may vary, depending on the research needs.
Researchers considering an application for use of this platform should contact Bharath Bynagari of DigiBiomarkers to discuss their project and receive a demonstration of the application platform prior to submission: bynagari@MavenSphere.com or 317-590-8275.